News Release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for US$150 million upon the closing of the transaction.
Good news for $NEU, who receive a one-third share, or $US50m.
$NEU had conservatively assumed they would get one third of US$100m of $US33m. So a small upside further boosting $NEU's cash reserves to press ahead with development of NNZ2591
A one-off, but good news.
NEXT: tomorrow morning's 3Q 2024 $ACAD numbers for DAYBUE sales.
Disc: $NEU held in RL and SM